Upfront Immunotherapy for NSCLC – OncLive
OncLive |
Upfront Immunotherapy for NSCLC
OncLive We’re going to talk first about immuno-oncology and immunotherapy. As you’re aware of, immunotherapy is now clearly a very exciting advance in the treatment of lung cancer. We’ve seen several approvals for agents targeting the immune checkpoint … |
|
AskBio and Columbus Venture Partners Launch Gene Therapy Company Viralgen
Business Wire (press release) CHAPEL HILL, N.C.–(BUSINESS WIRE)–Asklepios BioPharmaceutical, Inc. (AskBio) announced today the formation of Viralgen, a gene therapy joint venture with Columbus Venture Partners. The Viralgen Vector Core will use AskBio’s technology for the … |
Weekly Register |
BrainStorm Cell Therapeutics’ (BCLI) CEO Chaim Lebovits on Q3 2017 Results – Earnings Call Transcript
Seeking Alpha The first patients have been enrolled in the study and we’re also really pleased about the support that we’ve received from CIRM, California stem cell agency to provide funding for this important project. We are working with the top leading ALS centers … BrainStorm Announces Third Quarter 2017 Financial ResultsMarkets Insider BrainStorm Enrolls First Patients in Phase 3 Trial of NurOwn® in ALSGuruFocus.com (blog) Brainstorm Cell Therapeutics (NASDAQ:BCLI) Getting Somewhat Favorable Press Coverage, Report ShowsThe Ledger Gazette American Consumer News, LLC all 45 news articles » |